Trade Gilead GILD

Sell
 Buy

Gilead live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

Gilead News

Noah Lee 2025 Nov 10, 09:10

x402 Ecosystem Competition Analysis: Launchpads, Facilitators, and Providers

Frances Wang 2025 Nov 09, 16:00

Growth tech stocks to watch 2026: Nvidia (NVDA) stock, Netflix (NFLX)

Frances Wang 2025 Nov 09, 16:00

Crypto trading basics: What is Ethereum? Does ETH have any future?

Frances Wang 2025 Nov 09, 16:00

A guide to crypto ETFs: Bitcoin ETF vs. Ethereum ETF, what’s the difference?

Ava Grace 2025 Nov 08, 00:00

AI Funding Concerns Trigger Tech Stock Sell-Off

Sophia Claire 2025 Nov 08, 00:00

Gold Price Outlook: Currency Devaluation Trade Still Alive

Liam James 2025 Nov 08, 00:00

JPMorgan Sees Buying Opportunity Amid Market Jitters

Frances Wang 2025 Nov 06, 16:00

Gold and silver prices are up: what's happening to Gold (XAU/USD) and XAG?

Frances Wang 2025 Nov 06, 16:00

Nvidia Competitors Analysis (2026), NVDA Stock: AMD, Intel, Qualcomm, AVGO

Frances Wang 2025 Nov 05, 16:00

Crypto market update: Ethereum price drops, Bitcoin price falls below $104K

Latest news

Show more
Emma Rose 2025 Nov 10, 22:20

Bitdeer Stock Plummets Despite Revenue Surge & AI Pivot

Ava Grace 2025 Nov 10, 20:20

eToro's Q3 Surge: Driven by Crypto Trading, AI Innovation & Asset Growth

Noah Lee 2025 Nov 10, 20:10

Rumble to Acquire Northern Data with Tether's Backing: A Bold AI Play

Noah Lee 2025 Nov 10, 17:20

Crypto VC Funding in Q4: Trends and Key Deals Amidst Market Uncertainty

Ava Grace 2025 Nov 10, 16:40

Michael Saylor's Strategy Further Bolsters Bitcoin Holdings with $50 Million Purchase

Sophia Claire 2025 Nov 10, 13:30

UK & US Crypto 'Sandbox' in Development to Align Crypto Markets: Former MP

Ava Grace 2025 Nov 10, 13:10

Bitcoin Price Analysis: On the Brink of a Bear Market? A Deep Dive into Technicals and Macroeconomics

Sophia Claire 2025 Nov 10, 12:10

Assessing Bear Market Risk: A Bayesian Analysis for 2025 Q4

Info

Spread

0.71

Spread (%)

0.6026 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Tuesday

14:31 - 20:59

Monday

14:31-20:59

Wednesday

14:31-20:59

Thursday

14:31-20:59

Friday

14:31-20:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

147599278080

Shares Outstanding

1242000000

Earnings Date (Next)

2013-01-28

Div Yield

2025-12-30

Ex-Dividend Date

2025-12-15

Forward annual dividend rate

3.16

Forward annual dividend yield

0.0266

EPS

6.46

Learn more about this instrument

Gilead Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest Education Articles

Show more
Ghko B 2025 Nov 09, 16:00

Commodity trading: What is platinum, is it better to buy gold or platinum?

Ghko B 2025 Nov 09, 16:00

Gold price forecast 2025/2026/2027: How to analyze gold prices (XAU/USD)?

Ghko B 2025 Nov 06, 16:00

How to start cryptocurrency trading: how to trade BTC Price (BTC/USD) CFDs?

Trustpilot